Podcasts about ADT

Sarah opens up about starting opioids at 20, a rapid slide to heroin, pregnancy on methadone, jail, and the drug court program that helped her turn it around. After a later Xanax relapse during COVID, she did the work—therapy, structure, and service—and is now certified and working as a counselor at a maintenance clinic. This candid conversation with Wendy Beck and Rich Bennett shows what sustainable recovery really looks like—and why hope matters. Sponsored by Rage Against Addiction Guest Bio:  Sarah is a Harford County native, mom, and recovery professional. After entering opioid use at 20 and escalating to heroin in 2012, she experienced jail and drug court, achieved long-term abstinence from opiates and cocaine (since Sept. 27, 2016), overcame a benzodiazepine relapse in 2020–2021 (clean since Nov. 4, 2020), earned her Peer Recovery Specialist credential and ADT approval, and now counsels patients at a medication-assisted treatment clinic. Main Topics: ·         Podathon for Recovery: 12 Days of Hope benefiting Rage Against Addiction·         Starting opioids at 20; rapid progression from pills to heroin (2012)·         Pregnancy on methadone, stigma, and learning MAT safety·         IV use, crack/cocaine, legal consequences, and visible decline·         Jail detox and entry into Drug Court; Judge-led accountability·         Long-term sobriety from opiates/cocaine; COVID-era Xanax relapse and dangers of benzo withdrawal·         Therapy, boundaries, routines, fitness, and gratitude as core recovery tools·         Working in recovery: peer support vs. clinicians; women-specific needs; mom guilt and shame·         Maintenance meds (methadone/Suboxone): misuse stigma vs. real stability·         Parenting conversations about peer pressure and openness with kids·         Burnout prevention for recovery workers (self-care, phone boundaries, weekly therapy)  Resources mentioned: ·         Donate to Rage Against Addiction ·         Center for ASend us a textDonate HereRage Against AddictionRage Against Addiction is a non-profit organization dedicated to connecting addicts and their familiDisclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the showRate & Review on Apple Podcasts Follow the Conversations with Rich Bennett podcast on Social Media:Facebook – Conversations with Rich Bennett Facebook Group (Join the conversation) – Conversations with Rich Bennett podcast group | FacebookTwitter – Conversations with Rich Bennett Instagram – @conversationswithrichbennettTikTok – CWRB (@conversationsrichbennett) | TikTok Sponsors, Affiliates, and ways we pay the bills:Hosted on BuzzsproutSquadCast Subscribe by Email

Jessica Zwaan, Author of Built for People & COO at Talentful, joined us on The Modern People Leader.We talked about AI adoption in HR, from policy design to hands-on building. We explored the “Wild West” of AI use, tool selection, overcoming the stigma of ‘cheating,' and practical frameworks like the 4Bs (Bot, Build, Borrow, Buy) to guide adoption and innovation.---- Sponsor Links:

Pilar Muner, VP of People & Talent at ChartHop, joined us on The Modern People Leader.We covered:- Why fractional work isn't always the burnout cure-all it's made out to be-How ChartHop is using AI to power HR workflows in-house- The AI vendor checklist every HR leader needs — what to ask, what to watch for, and how to cut through the hypeIf you're evaluating AI tools for your people team, this episode will give you a practical lens on security, data integrity, and what to prioritize in vendor selection.---- Sponsor Links:

In today's episode, supported by Sumitomo, we spoke with Tanya B. Dorff, MD, about the use of androgen deprivation therapy (ADT) in patients with prostate cancer. Dr Dorff is section chief of the Genitourinary Disease Program, as well as a professor in the Department of Medical Oncology & Therapeutics Research at City of Hope in Duarte, California. In our conversation, Dr Dorff discussed the role of ADT in prostate cancer management, highlighting where this class of agents fits into National Comprehensive Cancer Network guidelines and how this class has evolved with the development of LHRH antagonists and agonists. She explained how the observational OPTYX study (NCT05467176), a registry of relugolix (Orgovyx) use, aims to address safety and efficacy in combination with androgen receptor pathway inhibitors in patients with advanced prostate cancer. She also noted how early data from OPTYX presented at the 2025 ASCO Annual Meeting showed relugolix's use in localized and metastatic settings. Dorff also talked through relugolix's safety profile, particularly regarding cardiovascular risk, as well as the quality-of-life effects associated with ADT. She also addressed strategies to mitigate financial toxicity, along with the potential for future ADT-sparing treatments.

Facing a rising PSA can be unsettling. But is early castration really the answer? In this episode, Dr. Stephen Petteruti walks through the harsh truth about androgen deprivation therapy (ADT), commonly known as medical castration. While often prescribed when PSA levels rise, he cautions that this drastic intervention is not without cost: loss of libido, cognitive decline, bone fractures, cardiovascular risks, and more. Instead of rushing into ADT at the first sign of trouble, Dr. Stephen urges a symptom-driven approach. He blends evidence, philosophy, and real-world experience to help men make smarter, more humane decisions at the edge of life and medicine.Ready to take control of your health decisions? Rethink what real prostate cancer care can look like. Tune in now: When Is Castration Worth Doing?Enjoy the podcast? Subscribe and leave a 5-star review on your favorite platforms.Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: www.intellectualmedicine.com Website: https://www.theprostateprotocol.com/ YouTube: https://www.youtube.com/@intellectualmedicine LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: instagram.com/intellectualmedine Consultation: https://www.theprostateprotocol.com/book-a-consultation Store: https://www.theprostateprotocol.com/store Community: https://www.theprostateprotocol.com/products/communities/v2/fightcancerlikeaman/home    Disclaimer:  The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com 

In a recent episode of the Oncology-on-the-Go podcast in collaboration with the American Psychosocial Oncology Society (APOS), host Daniel C. McFarland, DO, was joined by Christian J. Nelson, PhD, to discuss the often-overlooked subject of sexual health issues for men after cancer treatment. The discussion emphasized the importance of a nuanced approach to men's health, particularly in the context of genitourinary cancers like prostate and testicular cancer. McFarland is the director of the Psycho-Oncology Program at Wilmot Cancer Center and a medical oncologist who specializes in head, neck, and lung cancer in addition to being the psycho-oncology editorial advisory board member for the journal ONCOLOGY®. He opened the conversation by highlighting that while cancer's physical effects are well-documented, the mental and emotional toll is equally significant and often underappreciated in male patients. He highlighted that the field of psycho-oncology, which began with breast cancer, is now expanding to address men's specific needs. Men, he noted, are less likely to seek mental health support, yet have a higher risk of suicide, particularly at key moments in their cancer journey like diagnosis and recurrence. Nelson, chief of Psychiatry Service, attending psychologist, and codirector of the Psycho-Oncology of Care and Aging Program at Memorial Sloan Kettering Cancer Center, underscored that cancer treatments, especially for prostate cancer, often have profound adverse effects (AEs) that impact a man's sense of self and masculinity.  He detailed the effects of radical pelvic treatments and androgen deprivation therapy (ADT), which can lead to urinary incontinence, erectile dysfunction, and changes in sexual function and body image. These AEs can lead to feelings of being "broken," "inadequate," or "deflated." The pair discussed the "double-edged sword" of normalizing cancer, where patients are told their prognosis is good but are left unprepared for the life-altering AEs. This can lead to a sense of cognitive dissonance and isolation. The conversation stressed the need for clinicians to proactively normalize discussions about sexual health, making it clear that these are standard and expected aspects of the cancer experience. Both clinicians suggested that establishing a trusting relationship with patients is paramount and that referrals to psycho-oncology should be framed as an essential, not optional, component of treatment. They also recommend that clinicians consistently check in with their male patients about emotional and sexual well-being, even long after treatment has ended, to ensure they're coping with the lasting impacts of their experience. 

JooBee Yeow joined us on The Modern People Leader to talk about why HR must stop overfunctioning and start diagnosing real business problems—especially when revenue is on the line. We discussed how HR leaders can step out of their silo, challenge assumptions, influence revenue growth, and flip the HR pyramid to prioritize high-impact, strategic work.---- Sponsor Links:

Host Davide Soldato and guest Dr. John K. Lin discuss the JCO article "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-For-Service Beneficiaries with Metastatic Breast, Colorectal, Lung, and Prostate Cancer." TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato: Hello, and welcome to JCO After Hours, the podcast where we sit down with authors of the latest articles published in the Journal of Clinical Oncology. I'm your host, Dr. Davide Soldato, a medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by Dr. Lin, assistant professor in the Department of Health Services Research at the University of Texas MD Anderson Cancer Center. Dr. Lin and I will be discussing the article titled, "Racial and Ethnic Disparities Along the Treatment Cascade Among  Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." Thank you for speaking with us, Dr. Lin. Dr. Lin: Thank you so much for having me. I appreciate it. Dr. Davide Soldato: So, just to start, to frame a little bit the study, I just wanted to ask you what prompted you and your team to look specifically at this question - so, racial and ethnic disparities within this specific population? And related to this question, I just wanted to ask how this work is different or builds on previous work that has been done on this research topic. Dr. Lin: Yeah, absolutely. Part of the impetus for this study was the observation that despite people who are black or Hispanic having equivalent health insurance status - they all have  Medicare Fee-for-Service - we've known that treatment and survival differences and disparities have persisted over time for patients with metastatic breast, colorectal, lung, and prostate cancer. And so, the question that we had was, "Why is this happening, and what can we do about it?" One of the reasons why eliminating racial and ethnic disparities in survival among Medicare beneficiaries with metastatic cancer has been elusive is because these disparities are occurring along a lot of dimensions. Whether or not it's because the patient presented late and has very extensive metastatic cancer; whether or not the patient has had a difficult time even seeing an oncologist; whether or not the patient has had a difficult time starting on any systemic therapy; or maybe it's because the patient has had a difficult time getting guideline-concordant systemic therapy because, more recently, these treatments have become so expensive. Disparities, we know, are occurring along all of these different facets and areas of the treatment cascade. Understanding which one of these is the most important is the key to helping us alleviate these disparities. And so, one of our goals was to evaluate disparities along the entire treatment cascade to try to identify which disparities are most important. Dr. Davide Soldato: Thank you very much. That was very clear. So, basically, one of the most important parts of the research that you have performed is really focusing on the entire treatment cascade. So, basically, starting from the moment of diagnosis up to the moment where there was the first line of treatment, if this line of treatment was given to the patient. So, I was wondering a little bit, because for this type of analysis, you used the SEER-Medicare linked database. So, can you tell us a little bit which was the period of time that you selected for the analysis? Why do you think that that was the most appropriate time to look at this specific question? And whether you feel like there is any potential limitation in using this type of database and how you handled this type of limitations? Dr. Lin: Yeah, absolutely. It's a great question. And I want to back up a little bit because I want to talk about the entire treatment cascade because I think that this is really important for our research and for future research. We weren't the first people to look at along the treatment cascade for a disease. Actually, this idea of looking along the treatment cascade was pioneered by HIV researchers and has been used for over a decade by people who study HIV. And there are a lot of parallels between HIV and cancer. One of them is that with HIV, there are so many areas along that entire treatment cascade that have to go right for somebody's treatment to go well. Patients have to be diagnosed early, they have to be given the right type of antiretrovirals, they have to be adherent to those antiretrovirals. And if you have a breakdown in any one of those areas, you're going to have disparities in care for these HIV patients. And so, HIV researchers have known this for a long time, and this has been a big cornerstone in the success of getting people with HIV the treatment that they need. And I think that this has a lot of parallels with cancer as well. And so, I am hoping that this study can serve as a model for future research to look along the entire treatment cascade for cancer because cancer is, similarly, one of these areas that requires multidisciplinary, complex medical care. And understanding where it is breaking down, I think, is crucial to us figuring out how we can reduce disparities. But for your question about the SEER-Medicare linked database, so we looked between 2016 and 2019. That was the most recent data that was available to us. And one of the reasons why we were excited to look at this is because there were some new treatments that were just released and FDA-approved around 2018, which we were able to study. And this included immunotherapy for non–small cell lung cancer, and then it also included androgen receptor pathway inhibitors, the second-generation ones, for prostate cancer. And the reason why this is important is because for some time, as we have developed these new therapies, there's been a lot of concern that there have been disparities in access to these novel therapies because of how expensive they are, particularly for the Medicare population. And so one of the reasons why we looked specifically at this time period was to understand whether or not, in more recent years, these novel therapies, people are having increasing disparities in them and whether or not increasing disparities in these more expensive, newer therapies is contributing to disparities in mortality. That being said, obviously, we're in 2025 and these data are by now six years old, and so there are additional therapies that are now available that weren't available in the past. But I think that, that being said, at least it's sort of a starting point for some of the more important therapies that have been introduced, at least for non–small cell lung cancer and prostate cancer. And the database, SEER-Medicare, is helpful because it uses the population cancer registry, which is the SEER registry cancer registry, linked to Medicare claims. So, any type of medical care that's billed through Medicare, which is going to basically be all of the medical care that these patients receive, for the most part, we're going to be able to see it. And so, I think that this is a really powerful database which has been used in a lot of research to understand what kind of care is being received that has been billed through Medicare. So, one of the limitations with this database is if there is care that's received that was not billed through Medicare, we're not going to be able to see that. And this does not happen probably that frequently, particularly because most patients who have insurance are going to be receiving care through insurance. However, we may see it for some of the oral Part D drugs. Some of those drugs are so expensive that patients cannot pay for the coinsurance during that time. And it's possible that some of those drugs patients were getting for free through the manufacturer. We potentially missed some of that. Dr. Davide Soldato: So, going a little bit into the results, I think that these are very, very interesting. And probably the most striking one is that when we look at the receipt of any type of treatment for metastatic breast, colorectal, prostate, and lung cancer - and specifically when we look at guideline-directed first-line treatments - you observed striking differences. So, I just wanted you to guide us a little bit through the results and tell us a little bit which of the numbers surprised you the most. Dr. Lin: So, what we were expecting is to see large disparities in receiving what we called guideline-directed systemic therapy. And guideline-directed systemic therapy during this time kind of depended on the cancer. So, we thought that we were going to see large disparities in guideline-directed therapy because these were the more novel therapies that were approved, and thus they were going to be the more expensive therapies. And so, what this meant was for colorectal cancer, this was going to be any 5-FU–based therapy. For lung cancer, this was going to be any checkpoint inhibitor–based therapy. For prostate cancer, this was going to be any ARPI, so this was going to be things like abiraterone or enzalutamide. And for breast cancer, this was going to be CDK4 and 6 TKIs plus any aromatase inhibitor. And so, for instance, for breast, prostate, and lung cancer, these were going to be including more expensive therapies. And so, what we expected to see was large disparities in receiving some of these more expensive, novel therapies. And we thought we were going to see fewer disparities in receiving some of the cheaper therapies, such as aromatase inhibitors, 5-FU, older platinum chemotherapies for lung cancer, and ADT for prostate cancer. We were shocked to find that we saw large racial and ethnic disparities in seeing some of the older, cheaper chemotherapies and hormonal therapies. So for instance, for breast cancer, 59% of black patients received systemic therapy, whereas 68% of white patients received systemic therapy. For colorectal, only 23% of black patients received any systemic therapy versus 34% of white patients. For lung, only 26% of black patients received any therapy, whereas 39% of white patients did. And for prostate, only 56% of black patients received any systemic therapy versus 77% of white patients. And so, we were pretty shocked by how large the disparities were in receiving these cheap, easy-to-access systemic therapies. Dr. Davide Soldato: Thank you very much. So, I just wanted to go a little bit deeper in the results because, as you said, there were striking differences even when we looked at very old and also cheap treatments that, for the majority of the patients that were included inside of your study, were actually basically available for a very small price to these patients who had the eligibility for Medicare or Medicaid. And I think that one of the very interesting parts of the research was actually the attention that you had at looking how much of these disparities could be explained by several factors. And actually, one of the most interesting results is that you observed that low-income subsidy status was actually a big determinant of these disparities in terms of treatment. So, I just wanted to guide us a little bit through these results and then just your opinion about how these results should be interpreted by policymakers. Dr. Lin: Yeah, absolutely. I'm going to explain a little bit about what low-income subsidy status is and dual-eligibility status. Some of the listeners may not know what low-income subsidy status or dual-eligibility status is. Low-income subsidy status is part of Medicare Part D. Medicare Part D is an insurance benefit that allows patients to receive oral drugs. So these are drugs that are dispensed through the pharmacy, such as the CDK4/6 inhibitors, as well as second-generation ARPIs in our study. For patients who have Medicare Part D and whose income is low enough - falls below a certain federal poverty level threshold - those patients will receive their oral drugs for much cheaper. And this is really important for some of these more novel therapies because for some of these more novel therapies, if you don't have low-income subsidy status, you may be paying thousands of dollars for a single prescription of those drugs. Whereas if you have low-income subsidy status, you may be paying less than $10. And so that difference, greater than $1,000 or $2,000 versus less than $10, one would think that the patient who's paying less than $10 would be much more likely to receive those therapies. So that's low-income subsidy status. Low-income subsidy status, importantly, doesn't apply for infused medications like immunotherapy. But it's important to know that most people with low-income subsidy status - about 88% - are also dual-eligible. What dual-eligible means is that they have both Medicare and Medicaid. Medicare being the insurance that everybody has in our study who's greater than 65. And Medicaid is the state-run but federally subsidized insurance that patients with low incomes have. And so patients who are dual-eligible - and about 87% of those with low-income subsidy status are dual-eligible - those patients have both Medicaid and Medicare, and they basically pay next to nothing for any of their medical care. And that's because Medicare will reimburse most of the medical care and the copays or coinsurance are going to be covered by Medicaid. So Medicaid is going to pick up the rest of the bill. So, most of the patients who have low-income subsidy status who are dual-eligible, these patients pay almost nothing for their medical care - Part B or Part D, any of their drugs. And so, one would expect that if cost were the main determinant of disparities in cancer care, then one would expect that dual-eligibles, most of them would be receiving treatment because they're facing minimal to no costs. What we found is that when we broke down the racial and ethnic disparity by a number of factors - including LIS status/dual eligibility, age, the number of comorbidities, etcetera - what we found was that the LIS or dual-eligibility status explained about 20% to 45% of the disparities that we saw in receiving treatment. And what that means is despite these patients paying next to nothing for their drugs, these are the most likely patients to not be treated for their cancer at all. So they're most likely to basically be diagnosed, survive for two months, see an oncologist, and then never receive any systemic therapy for their cancer. And this is not just chemotherapies for colorectal or lung cancer. This includes cheaper, easier-to-tolerate hormonal therapies that you can just take at home for breast cancer, or you can get every six months for prostate cancer, that people who even have poorer functional status are able to take. However, for whatever reason, these dual-eligible or LIS patients are very unlikely to receive treatment compared to any other patient. The low likelihood of treating this group of patients, that explains a large portion of the racial and ethnic disparities that we see. Dr. Davide Soldato: And one thing that I think is very interesting and might be of potential interest to our listeners is, did you compare survival outcomes in these different settings? And did you observe any significant differences in terms of racial and ethnic disparities once you saw that there was a significant difference when looking at both receipt of any type of treatment and also guideline-directed treatments? Dr. Lin: We saw that there were large disparities in survival by race and ethnicity when you look overall. However, when you just account for the patients who received any systemic therapy at all - not just guideline-directed systemic therapy - those differences in survival essentially disappeared. And so, what that suggests is that if black patients were just as likely to receive any systemic therapy at all as white patients, we would expect that the survival differences that we were seeing would disappear. And this is not even just looking at guideline-directed systemic therapy. This was looking just at systemic therapy alone. And so, while guideline-directed systemic therapy should be a goal, our research suggests that if we are to close the gap in disparities in overall survival among black and white patients, we must first focus on patients just receiving any type of treatment at all. And that should be the very first focus that policymakers, that leaders in ASCO, that health system leaders, that physicians, that we should focus on: just trying to get any type of treatment to our patients who are poorer or black. Dr. Davide Soldato: Thank you very much. And this was not directly related to the research that you performed, but going back to this very point - so, increasing the number of patients that receive any kind of systemic treatment before looking at guideline-directed treatments - what would you feel would be the best way to approach this in order to decrease the disparities? Would you look at interventions such as financial navigation or maybe improving referral pathways or providing maybe more culturally adapted information to the patients? Because in the end, what we see is disparities based on racial and ethnicity. We see that we can reduce these disparities if we get these patients to the treatment. But in the end, what would you feel is the best way to bring patients to these types of treatments? Dr. Lin: I think the most important thing is to understand that these disparities are not primarily happening because of the high cost of cancer treatment. These disparities are happening because of other social vulnerabilities that these patients are facing. And so these vulnerabilities could be a lot of things. It could be mistrust of the medical system. It could be fear of chemotherapy or other treatments. It could be difficulty taking time off of work. It could be any number of things. What we do know is when we've looked at the types of interventions that can help patients receive treatment, navigation is probably the most effective one. And the reason why I think that is because when patients don't receive treatment because of social vulnerability, I sort of look at social vulnerability like links in a chain. Any weakest link is going to result in the patient not receiving treatment. This may be because they have a hard time taking time off of work. This may be because they had a hard time getting transportation to their physician. It may be because they had an interaction with a physician, but that interaction was challenging for the patient. Maybe they mistrusted the physician. Maybe they're worried about the medical system. If any of these things goes wrong, the patient is not going to be treated. The patient navigator is the only person who can spot any of those weak links within the chain and address them. And so, I think that the first thing to do is to get patient navigation systems in place for our vulnerable patients throughout the United States. And this is incredibly important because in Medicare, patient navigation is reimbursable. And so this is not something that's ‘pie in the sky'. This is something that's achievable today. The second thing is that it's really important that we see these vulnerabilities happening for patients who are dual-eligible, who have both Medicare and Medicaid. One of the reasons why this is important is because there has been a lot of research outside of what we've done that has shown vulnerabilities for dual-eligible patients who have Medicare for a number of different diseases. And the reason why is because, although patients are supposed to have the benefits of both Medicare and Medicaid, usually these two insurances do not play nicely together. It creates a huge, bureaucratic, complex mess and maze that most of these patients are unable to navigate. And so many of these patients are unable to actually receive the full reimbursement from both Medicare and Medicaid that they should be getting because those two insurers are not communicating well. And so the second thing is that national cancer organizations need to be supporting policies and legislation that is already being discussed in Congress to revamp the dual-eligible system so that it facilitates these patients getting properly reimbursed for their care from both Medicare and Medicaid and these systems working together well. The third thing is that Medicaid itself has many benefits that can allow patients to receive care, like they have transportation benefits so that patients can get to and from their doctor's appointments with ease. And so I think this will be additionally very, very helpful for patients. The last thing is, you know, it's possible that future innovations such as telemedicine and tele-oncology and cancer care at home can also make it easier for some of these patients who may be working a lot to receive care. But what I would say is that our study should be a call for healthcare delivery researchers to start piloting interventions to be able to help these patients receive systemic therapy. And so what this could look like is trying to get that care navigation and implement that in clinics so that patients can be receiving the care that they need. Dr. Davide Soldato: Thank you very much. That was a very clear perspective on how we can tackle this issue. So, I just wanted to close with a sort of personal question. I was wondering what led you to work specifically in this research field that is very challenging, but I think it's particularly critical in healthcare systems like in the United States. Dr. Lin: Yeah, absolutely. One of the most important things for me as an oncologist and a researcher is being able to know that all patients in the United States - and obviously abroad - who have cancer should be able to receive the kind of care that they deserve. I don't think that patients, because their incomes are lower or because their skin looks a certain color or because they live in rural areas, these shouldn't be determinants of whether or not cancer patients are receiving the care that they need. We can develop and pioneer the very best treatments and breakthroughs in oncology, but if our patients are not receiving them - if only 20% of our patients with colon cancer or lung cancer are receiving any type of systemic therapy, who are black - this is a big problem. But this is something that I think that our system can tackle. We need to get these breakthroughs that we have in oncology to every single cancer patient in America and every single cancer patient in the world. I think this is a goal that all oncologists should have, and I think that this is something that, honestly, is achievable. I think that research is a powerful tool to give us a lens into understanding exactly why it is that certain patients are not getting the care that they deserve. And my goal is to continue to use research to shed light on why our system is not performing the way that we all want it to be. Dr. Davide Soldato: Circling back to your research, actually the manuscript that was published was supported by a Young Investigator Award by the American Society of Clinical Oncology. So, was this the first step of a more broad research, or do you have any further plans to go deeper in this topic? Dr. Lin: Yeah, absolutely. First, I want to thank the ASCO Young Investigator Award for funding this research because I think it's fair to say that this research would not have happened at all without the support of the ASCO YIA. And the fact that ASCO is doing as much as it can to support the future generation of cancer researchers is incredible. And it's a huge resource, and having it come at the time that it did is critical for so many of us. So I think that this is an unbelievable thing that ASCO does and continues to do with all of its partners. For me, yeah, this is definitely a stepping stone to further research.  Medicare Fee-for-Service is only one part of the population. I want to spread this research and extend it to patients who have other types of insurances, look at other types of policies, and also try to conduct some of the cancer care delivery research that's needed to try to pilot some interventions that can resolve this problem. So hopefully this is the first step in a broader series of studies that we can all do collectively to try to eliminate racial and ethnic disparities in cancer care and survival. Dr. Davide Soldato: So, I think that we've come at the end of this podcast. Thank you again, Dr. Lin, for joining us today. Dr. Lin: Thank you so much. It was a pleasure to be a part of this. Dr. Davide Soldato: So, we appreciate you sharing more on your JCO article, "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Tiffany Stevenson, former Chief People Officer at WeightWatchers and Patreon, joined us on The Modern People Leader. We talked about this being the CHROs toughest chapter yet, how AI is reshaping HR, and what HR brings to the boardroom.---- Sponsor Links:

This week, Dr. Joel Kahn reviews the latest research on men's health, focusing on diet and prostate cancer. He highlights findings that support whole-food, plant-based diets and discusses the connection between prostate cancer, heart disease, and the cardiovascular risks associated with androgen deprivation therapy (ADT). Other topics covered include plant-based diets and disease rates, the role of LDL cholesterol in soft plaque formation, TMAO in abdominal aortic aneurysms and kidney disease, periodontal disease and its impact on heart health, saccharin and cardiovascular risk, extreme physical activity and carotid plaque, and the effects of Tylenol use during pregnancy.  Dr. Kahn also reviews new research on cyclodextrin suppositories, a paper examining the impact of statins on blood sugar, and the potential role of TUDCA as a possible antidote.  Resources mentioned in this episode include the cyclodextrin paper available at www.atherocare.com/drjoelkahn and details on TUDCA at https://shop.drjoelkahn.com/catalog/product/view/id/17560/s/tudca-tauroursodeoxycholic-acid-60-capsules/. Special thanks to our sponsor Igennus.com, use discount code DrKahn for all products.

Priscila Bala, CEO of LifeLabs Learning, joined us on The Modern People Leader.We explored how AI is transforming learning, the enduring role of middle management, and why the most impactful leadership skills are more human than ever.---- Resources Mentioned:

This week on The Vergecast, the co-founder and former CEO of iRobot, Colin Angle, joins The Verge's smart home reviewer, Jennifer Pattison Tuohy, to discuss what the ideal home robot is. Are we close to creating a Rosie the Robot — an all-in-one humanoid robot that can take care of our homes, or should we take an entirely different approach to home robotics? They dive into the advances in technology powering this shift and ponder what purpose robotics in the home should really serve. Then, Jen takes a journey back into smart home history to help us understand its future. Grant Erickson, Principal of Nuovations, a former Apple, Nest, and Google engineer who was part of the team that developed Thread, joins the show. He shares the story of how and why, back in 2011, the Nest team, led by Tony Faddell and Matt Rogers, decided to create a smart home protocol. It involves a thermostat, fragmented ecosystems, and one of the best smart home products ever made. They discuss how Thread became the foundation of the Matter smart home standard — an unprecedented industry collaboration with a herculean task — to make the smart home simpler. To close out the show, Grant sticks around to help answer a Vergecast hotline question (call 866-VERGE11 or email vergecast@theverge.com) about how Matter manages your data. Further reading: Maybe I don't want a Rosey the Robot after all Amazon left Roomba with a huge mess to clean up Figure will start ‘alpha testing' its humanoid robot in the home in 2025 Amazon Astro review: too much Alexa, not enough arms Samsung is finally releasing Ballie This Pixar-style dancing lamp hints at Apple's future home robot iRobot's founder is working on a new kind of home robot iRobot OS is the newest ‘brain' for your Roomba Amazon bought iRobot to see inside your home I tested a robot vacuum with an arm, and my dog may never forgive me Inside the Nest: iPod creator Tony Fadell wants to reinvent the thermostat Nest CEO Tony Fadell on Google acquisition Fire drill: Can Tony Fadell and Nest build a better smoke detector? How big companies kill ideas — and how to fight back, with Tony Fadell Situation: there are too many competing smart home standards Matter's plan to save the smart home Nest's home security system costs $499 and comes with magnetic door sensors Google says Matter is still set to fix the biggest smart home frustrations Thread is Matter's secret sauce for a better smart home Nanoleaf launches a smart switch after eight years of trying Thread count: Ikea is stitching together a smarter home Why Thread is Matter's biggest problem right now The four changes in Thread 1.4 that could fix the protocol It could be 2026 before all your Thread border routers work together Matter will be better in 2025 — say the people who make it The Nest Learning Thermostat gets its biggest upgrade in over a decade killedbygoogle.com Google's ADT partnership finally has a new home security product to show for it Google discontinues Nest Protect smoke alarm and Nest x Yale door lock Google discontinues its Google Nest Secure alarm system Appliance makers are teaming up to reduce your electricity usage — and save you cash Learn more about your ad choices. Visit podcastchoices.com/adchoices

Rajia Abdelaziz is the CEO and co-founder of invisaWear, a company at the forefront of smart jewelry and life-saving technology. An advocate for women's and children's safety, Rajia scaled invisaWear to reach over 100,000 customers, successfully raised millions of dollars, and earned coveted recognition including Forbes' 30 Under 30 North America, Boston Globe's Tech Power Players, BostInno's 25 Under 25, and the New England Innovations Award. Just last week invisaWear was selected by Oprah Winfrey for this year's Back to School List. As a minority female CEO, Rajia is passionate about mentoring other young entrepreneurs to pursue their dreams and beat the odds, guiding aspiring entrepreneurs at UMass Lowell's Entrepreneurship program.

What do Lions Rugby and Cardio-oncology have in common?? Well tune in to this episode of GU Cast to find out! The incidence of cardiovascular disease is high in our patients with advanced prostate cancer (more than maybe we appreciate), plus fundamental treatments such as androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) further increase the risk of cardiovascular events. And now there is a multidisciplinary field called cardio-oncology which is set to address all of this. How do we (simply) assess cardiovascular risk? Who needs to be optimised? What do we need to know about LHRH analogues vs anatagonists? What about ARPIs and drug-drug interactions with statins and blood thinners? Superb studio guest today to discuss all of this, and our first ever Cardiologist! Dr Alex Lyon (Royal Brompton Hospital, London) is a world renowned expert in cardio-oncology and joined us to run through a bit of a dummy's guide to prostate cardio-oncology. With your usual hosts, Renu Eapen and Declan Murphy.This is a Themed Podcast supported by our Bronze Partners, Cipla. Even better on our YouTube channel.

Help MuggleCast grow! Become a MuggleCast Member and get great benefits like Bonus MuggleCast! Patreon.com/MuggleCast  Grab official merch! MuggleCastMerch.com Pick up overstock merch from years past, including our 19th Anniversary Shirt! MuggleMillennial.Etsy.com On this week's episode, news continues to roll in on the new Harry Potter TV Show. Join Andrew, Eric, Micah and Laura as they talk the latest casting news and first looks before busting open the MuggleMail bag to take your feedback on the last few chapters of Order of the Phoenix! News: Our first look at Dominic McLaughlin as The Boy Who Lived and Nick Frost as Hagrid! Plus, four new casting announcements: Rory Wilmot as Neville Longbottom, Amos Kitson as Dudley Dursley, Louise Brealey as Madam Rolanda Hooch, and Anton Lesser as Garrick Ollivander. And those Dursleys are looking mighty 90s in these behind-the-scenes photos! Voicemails cover Snape's Worst Memory, Harry's Career Aspirations, Grawp and how the Pensieve could have altered the end of Order of the Phoenix! Why is Harry so obsessed with Dumbledore? He barely knows the guy! How exactly did Tom Riddle's curse on the Defense Against The Darks Arts position work? Old habits die hard! Did Rita Skeeter actually turn over a new leaf? One listener questions if there really was a binding magical contract with the Goblet of Fire or if it was all secretly part of Dumbledore's larger plan! Put your memories away! Did Snape bait Harry to look in the Pensieve? Were Hermione's comments about Firenze really a commentary on Lavender and Parvati's fawning over their new Divination teacher? Comparing the Marauder's treatment of Snape to the Death Eaters treatment of the Roberts family Reducto! Why couldn't Voldemort just shrink himself to gain access to the Ministry and get the prophecy himself? Chicken Soup For The MuggleCast Soul Chapter-by-Chapter returns next week with Order of the Phoenix, Chapter 33: Fight and Flight Quizzitch: In this chapter Umbridge placed Stealth Sensor Spells around her office door. Founded by Edward Calahan over 150 years ago, the company which currently holds at least 15% of the market share for home security systems, is called ADT. What does ADT stand for? Join in on the fun! In this week's Bonus MuggleCast, we look back at the Summer of Potter - 2007 saw the release of both Deathly Hallows and the Order of the Phoenix movie! Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Drop In CEO podcast Errol Allen shares insights on helping C-Suite leaders and organizations enhance their process efficiency, reduce costs, and achieve better business outcomes. Errol delves into the importance of process documentation, the role of CEOs in leading these initiatives, and the benefits of thorough documentation for training and internal operations. Highlighted is a case study where Errol helped a company streamline operations, resulting in improved morale, better performance, and increased company value. Tune in to learn how to overcome resistance in process documentation and when to consider automation for optimal efficiency. Episode Highlights: 02:15 Errol's Personal and Professional Journey 10:27 The Importance of Process Documentation 21:22 Navigating Resistance and Achieving Buy-In Errol Allen is a process improvement and systems expert who helps organizations align people, processes, and technology for better efficiency and ROI. With a hands-on approach shaped by roles at companies like ADT, GEICO, and The Houston Post, Errol launched his consulting business in 2011 to pursue his passion for smart systems and stellar service. He facilitates cross-functional process improvements across industries like property management, logistics, and manufacturing. A Houston native and natural storyteller, Errol’s insights have been featured in the Houston Business Journal, Customer Experience Magazine (UK), and more. His favorite saying? “I’m just having fun!” Connect with Errol Allen: LinkedIn: https://www.linkedin.com/in/errolallen/ Company Website: http://www.errolallenconsulting.com For more information about my services or if you just want to connect and have a chat, reach out at: https://dropinceo.com/contact/See omnystudio.com/listener for privacy information.

Help MuggleCast grow! Become a MuggleCast Member and get great benefits like Bonus MuggleCast! Patreon.com/MuggleCast  Grab official merch! MuggleCastMerch.com Pick up overstock merch from years past, including our 19th Anniversary Shirt! MuggleMillennial.Etsy.com On this week's episode, we discuss the events of Chapter 32 of Order of the Phoenix, "Out of the Fire." Join Andrew, Eric, Micah, and Pam as they cover the second attempted break-in to Professor Umbridge's office, and the fallout. Chapter-by-Chapter continues with Harry Potter and the Order of the Phoenix, Chapter 32: Out of the Fire Our Time Turner segment takes us back to Episode 470 of MuggleCast, titled “Silky Smooth Snape.” Should Harry have known that his vision was a ruse? The hosts go all-in on listing several signs, and whether they alone reveal the truth. Micah connects the threads between Sirius and Harry in books 3 and 5. What is Hermione getting at by mentioning Harry's 'saving people thing'? Often times, Harry has legitimately been left to fix the Hogwarts problem and save people. Can we blame him? We discuss the power lust present in both Umbridge and Draco, and how they need each other at this time. Umbridge's treatment of Snape is interesting, since she does trust he's as horrible as she is. What Hermione does works perfectly on Umbridge. Why? Why aren't the two other heads of House, Flitwick and Sprout, also members of the Order? Is Dumbledore skeptical of their loyalty, or is he just giving them a break?? The hosts have differing ideas about what being a 'bad mofo' means, when rating who the baddest was in this chapter. Our Lynx Line patrons answer the question, when was a time that you successfully thought on your feet the way Hermione does with Umbridge? Quizzitch: In this chapter Umbridge placed Stealth Sensor Spells around her office door. Founded by Edward Calahan over 150 years ago, the company which currently holds at least 15% of the market share for home security systems, is called ADT. What does ADT stand for? Join in on the fun! Learn more about your ad choices. Visit megaphone.fm/adchoices

In this presentation, UCSF's Dr. Eric Small explains the role of androgen deprivation therapy (ADT) in prostate cancer treatment across various stages of the disease. He discusses how prostate cancer cells rely on testosterone to grow and how medications can effectively reduce testosterone levels by targeting hormone signals or blocking production. Dr. Small outlines the different forms of ADT—injectables, implants, and pills—and reviews their pros, cons, and side effect profiles, including cardiovascular considerations. He also describes how combining ADT with newer androgen signaling inhibitors has improved survival outcomes in patients with metastatic or recurrent disease. The talk emphasizes the importance of balancing treatment benefits with side effects and highlights the role of shared decision-making in choosing the right approach. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40799]

In this presentation, UCSF's Dr. Eric Small explains the role of androgen deprivation therapy (ADT) in prostate cancer treatment across various stages of the disease. He discusses how prostate cancer cells rely on testosterone to grow and how medications can effectively reduce testosterone levels by targeting hormone signals or blocking production. Dr. Small outlines the different forms of ADT—injectables, implants, and pills—and reviews their pros, cons, and side effect profiles, including cardiovascular considerations. He also describes how combining ADT with newer androgen signaling inhibitors has improved survival outcomes in patients with metastatic or recurrent disease. The talk emphasizes the importance of balancing treatment benefits with side effects and highlights the role of shared decision-making in choosing the right approach. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40799]

In this presentation, UCSF's Dr. Eric Small explains the role of androgen deprivation therapy (ADT) in prostate cancer treatment across various stages of the disease. He discusses how prostate cancer cells rely on testosterone to grow and how medications can effectively reduce testosterone levels by targeting hormone signals or blocking production. Dr. Small outlines the different forms of ADT—injectables, implants, and pills—and reviews their pros, cons, and side effect profiles, including cardiovascular considerations. He also describes how combining ADT with newer androgen signaling inhibitors has improved survival outcomes in patients with metastatic or recurrent disease. The talk emphasizes the importance of balancing treatment benefits with side effects and highlights the role of shared decision-making in choosing the right approach. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40799]

In this presentation, UCSF's Dr. Eric Small explains the role of androgen deprivation therapy (ADT) in prostate cancer treatment across various stages of the disease. He discusses how prostate cancer cells rely on testosterone to grow and how medications can effectively reduce testosterone levels by targeting hormone signals or blocking production. Dr. Small outlines the different forms of ADT—injectables, implants, and pills—and reviews their pros, cons, and side effect profiles, including cardiovascular considerations. He also describes how combining ADT with newer androgen signaling inhibitors has improved survival outcomes in patients with metastatic or recurrent disease. The talk emphasizes the importance of balancing treatment benefits with side effects and highlights the role of shared decision-making in choosing the right approach. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40799]

What is the role of PSA for early detection, and how does hormone therapy affect cancer patients? These are questions we dig into in this episode. https://bit.ly/4lC0ZUdIn This Episode:01:32 - Road Trip-South Carolina & Shout Halellujah Potato Salad02:38 - Fighting For Your Life Is Boring - Andrew Reynolds04:44 - Prostate Cancer - Risks and Treatment09:46 - Why Was Biden's Prostate Cancer Detected So Late?14:52 - Signs and Symptoms of Prostate Cancer16:08 - Gleason Scoring for Prostate Cancer Grade19:18 - Hormone Therapy - Androgen Deprivation33:27 - Prostate Cancer and Partners36:21 - OutroAbout 1 in 8 men will be diagnosed with prostate cancer during their lifetime. Prostate cancer is the second-leading cause of cancer death in American men, behind lung cancer. Learn signs and symptoms, the role of PSA (prostate-specific antigen) for early detection and monitoring, how androgen-blocking therapy works, and how it affects patients and their partners.Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

We were joined by people leaders from Glassdoor, Asana, and Upstart. We talked about the fragmented burnout and how it's hitting people differently, how performance expectations have shifted in the last 6-12 months, and more.---- Sponsor Links:

In this podcast episode, host Seamus introduces the SoSecure app by ADT, a free iOS emergency assistance application designed to connect users quickly with ADT agents who can contact emergency services on their behalf. Seamus offers a detailed walkthrough of the app's features, accessibility, and functionality, highlighting its usefulness—especially for those who rely on VoiceOver or have specific communication needs.Listeners are guided through the app's setup, key functions, and helpful tips to maximize its effectiveness and accessibility. Whether you are visually impaired, need a silent way to communicate during emergencies, or simply want a reliable safety app, this episode provides a thorough overview to get you started.SoSecure by ADT is a personal emergency response app that offers an emergency button with PIN cancellation, automated guardian text notifications, silent SOS chat, and location tracking groups. It is accessible to VoiceOver users and free to download on iOS devices, making it an essential tool for safety and peace of mind in situations where calling 911 directly isn't possible.Key Topics Covered:Introduction to ADT and SoSecure Seamus explains ADT's long history as a home security company and clarifies that the SoSecure app does not require an ADT home security system to be used.App Accessibility The app is about 95% accessible with VoiceOver, with a few minor limitations noted.Account Setup Users are required to create an account that includes providing an email, phone number, and a profile picture. A four-digit PIN must be created to cancel emergency calls.Emergency Button Functionality The app features a large emergency button that, when pressed, initiates a 10-second countdown during which the user can cancel the call by entering their PIN. If not canceled, an ADT agent contacts the user and, if necessary, emergency services.Automated Guardian Contacts Users can add up to five guardians (emergency contacts) who receive automated text alerts in an emergency, sent directly from ADT's system.SOS Chat Feature Text chat is available within the app to communicate with ADT agents silently, beneficial for those who are deaf, hard of hearing, or in situations where verbal communication is unsafe.Location Sharing and Groups The app includes a "My Groups" feature, similar to location tracking apps, allowing users to track and receive notifications about group members' locations, though this feature has limited accessibility.Settings Overview Seamus details the settings menu, including account editing, notification controls, PIN management (which requires a verification text), FAQ access, and legal/contact information.Demonstration of Adding and Removing Guardians The process of adding contacts from the user's phone and removing them is shown, with accessibility tips for blind users.Emergency Button Demonstration Seamus demonstrates using the emergency button and entering the PIN to cancel a test emergency call.Why Seamus Likes the App Seamus highlights the app's usefulness, especially when in unfamiliar locations or…

Jessica Zwaan joined us again to unpack the metrics that actually matter in HR today. We talked about the three buckets of metrics every People Leader should use, why the RANS test is a better way to measure engagement, and the one metric to rule them all (ELTV:CAC). ---- Sponsor Links:

Filipe Espósito faz uma visita ao ADT para contar como anda sua vida de criador de conteúdo, e qual é a cordo vestido do iOS.

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

The Ramblin Gambler fields questions about working with independent casinos hosts, including how to boost your ADT score.

AUA2025: AUA Advanced Prostate Cancer Course CME Available: https://auau.auanet.org/node/43035 At the conclusion of this activity, participants will be able to: 1. Describe appropriate use of genetic testing (germline) and understand the importance of genetic counseling. 2. Describe appropriate use of somatic testing and treatments related to specific genetic alterations. 3. Identify appropriate combination therapy with ADT plus novel androgen access therapies and chemotherapy. Early treatment intensification including patient selection and adverse effects and benefits will be discussed in mHSCPC. 4. Explain the treatments for non-metastatic CRPC and oncologic outcomes, with recommendations based on AUA/SUO Guidelines. 5. Counsel patients on available treatment options for CRPC as well as combination therapy and sequencing based on the latest AUA/SUO Guidelines. ACKNOWLEDGEMENTS: This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Frieda Möcker, Head of People & Culture at Sastrify, joined us on The Modern People Leader. We talked about the first steps she took to treat HR more like a product, how her team does sprint planning, and why she prefers “NCTs” over OKRs.---- Sponsor Links:

The Big Unlock Podcast · Reimagining Healthcare From Meaningful Use of Data to AI-Driven Equity – Podcast with Aneesh Chopra In this episode, Aneesh Chopra, Chief Strategy Officer at Arcadia shares a bold vision for advancing healthcare equity through smarter data use, AI, and workflow innovation. He unpacks the journey from the early days of “meaningful use” to today's AI-powered, value-based care landscape, highlighting how intelligent workflows can reach underserved populations and improve outcomes at scale. Aneesh introduces the concept of a “healthcare information fiduciary,” a model where apps and platforms act solely in the patient's best interest, free from institutional financial incentives. He discusses how this, combined with emerging AI capabilities and interoperability standards like CMS's FHIR APIs, can empower consumers and scale high-impact care delivery. With real-world success stories, from improved hospital ratings via conversational AI to national gains in ADT data coverage, this episode offers healthcare leaders a roadmap for driving innovation through public-private collaboration and patient-centered data strategy. Take a listen.

  What if your journey to becoming a physician didn't come with the burden of student debt, and instead, offered unique career opportunities and a profound sense of purpose? Join us as we chat with Army LTC Mary Alice Noel, MD, Navy CAPT Shauna F. O'Sullivan, DO, and Air Force Col Brian Neubauer, MD, to uncover the transformative power of the Health Professions Scholarship Program (HPSP). These esteemed guests share how the program not only covers full medical school tuition and provides a monthly stipend, but also opens doors to a diverse array of career paths in military medicine, offering a rewarding way to serve one's country.     Our discussion doesn't stop at financial benefits; it dives deep into the commitments and training opportunities that come with the HPSP. We unravel the journey through military medical training, from officer training schools to active duty for training (ADT) activities, and the unique advantages of being a Medical Corps officer during residency. You'll hear about the high match rates in military Graduate Medical Education (GME), the opportunities to pursue desired specialties, and the robust support systems that ensure both professional and personal growth.    The episode also highlights the rewarding nature of military deployments, beyond the traditional roles, with stories of humanitarian missions and crisis support. Learn about the vast opportunities available to military physicians, including roles in aviation and space, and the collaborative environments that enhance career development. Whether you're considering a future in military medicine or are just curious about the path less taken, this conversation is packed with insights and experiences that illustrate the immense fulfillment and camaraderie found in serving as a military physician. Chapters: (00:04) Health Professions Scholarship Program Overview (13:54) Military Medical Training and Benefits (24:30) Military GME and Residency Opportunities (36:54) Additional Training Opportunities (44:49) Military Medicine Career Opportunities (54:48) Military Medicine Deployments (01:04:15) Military Medicine Tribute and Resources   Chapter Summaries: (00:04) Health Professions Scholarship Program Overview   HPSP fully funds medical school for military physicians, offering financial benefits, unique training opportunities, and collaborative nature of military medicine.   (13:54) Military Medical Training and Benefits   HPSP journey includes officer training, ADT, service obligations, and benefits during residency for aspiring military medical officers.   (24:30) Military GME and Residency Opportunities   Military GME process for HPSP students includes a separate match, active duty tours, and high match rates for desired specialties.   (36:54) Additional Training Opportunities   Air Force physicians have various opportunities in residency, fellowships, and careers in clinical, academic, command, and integrated operations.   (44:49) Military Deployment and Career Opportunities   Nature's multifaceted military deployments offer diverse opportunities for training and career tracks, including GME and operational care for soldiers.   (54:48) Military Medicine Deployments   The HPSP offers financial freedom, unique deployment experiences, and leadership development in military medicine.   (01:04:15) Military Medicine Tribute and Resources   We thank all American service members and their families, highlighting their patriotism and invite listeners to explore the WarDocs podcast to find out more about the history and proud legacy of Military Medicine.     Take Home Messages: Financial Benefits of HPSP: The Health Professions Scholarship Program (HPSP) offers substantial financial advantages for aspiring military physicians, including full tuition coverage for medical school and a monthly stipend. This program offers the opportunity to graduate without the burden of student debt, making it an attractive option for those interested in pursuing a medical career within the military.   Diverse Training Opportunities: Military medicine offers unique training experiences, such as active duty for training (ADT) and clinical rotations at military hospitals across the country. These experiences, along with the opportunity to participate in both military and civilian residency programs, provide HPSP participants with a comprehensive and competitive medical education.   Career Pathways in Military Medicine: The military medical career offers a variety of pathways, including clinical, academic, command, and integrated operations roles. This flexibility allows physicians to explore different aspects of medicine and leadership within the Army, Navy, and Air Force.   Deployment and Humanitarian Roles: Military deployments offer rewarding experiences beyond traditional combat roles, including humanitarian assignments and support for civilian institutions during crises. These roles provide a sense of purpose and camaraderie, highlighting the impact military physicians can have on a global scale.   Comprehensive Support During Residency: Military Medical Corps officers benefit from competitive salaries, comprehensive insurance, and generous leave policies during residency. These benefits create a supportive environment that balances professional growth with personal life, ensuring the well-being of military physicians and their families.   Link for more information: Navy:  Navy HPSP: https://www.med.navy.mil/Accessions/Health-Professions-Scholarship-Program-HPSP-and-Financial-Assistance-Program-FAP/ Navy Medicine Recruiting - https://www.navy.com/careers-benefits/careers/medical/physician Navy Medical Corps - https://www.med.navy.mil/Medical-Corps/ Army: Army HPSP: https://www.goarmy.com/careers-and-jobs/specialty-careers/medical/amedd-scholarships Air Force: Air Force HPSP: https://www.airforcemedicine.af.mil/Organizations/Physician-Education-Branch/Medical-School-Scholarships/ Air Force Medical Corps: https://www.airforcemedicine.af.mil/About-Us/Medical-Branches/Medical-Corps/ Graduate Medical Education (GME): DHA GME Website: https://www.health.mil/Military-Health-Topics/DHA-GME Navy GME - https://www.med.navy.mil/Naval-Medical-Leader-and-Professional-Development-Command/Professional-Development/Graduate-Medical-Education/   Episode Keywords: Military Medicine, HPSP, Health Professions Scholarship Program, Medical Education, Army Medical Corps, Navy Medicine, Air Force Physicians, Medical Career, Military Hospitals, Military Match System, Graduate Medical Education, Medical Residency, Military Deployment, Humanitarian Assignments, Operational Roles, Military Scholarships, Medical Corps Officer, War Docs Podcast, Medical Training Opportunities   Hashtags: #MilitaryMedicine #HPSP #MedicalEducation #MilitaryCareer #ArmyNavyAirForce #HealthcareScholarship #MedicalTraining #WarDocsPodcast #MilitaryPhysicians #GraduateMedicalEducation     Honoring the Legacy and Preserving the History of Military Medicine The WarDocs Mission is to honor the legacy, preserve the oral history, and showcase career opportunities, unique expeditionary experiences, and achievements of Military Medicine. We foster patriotism and pride in Who we are, What we do, and, most importantly, How we serve Our Patients, the DoD, and Our Nation.   Find out more and join Team WarDocs at https://www.wardocspodcast.com/ Check our list of previous guest episodes at https://www.wardocspodcast.com/our-guests Subscribe and Like our Videos on our YouTube Channel: https://www.youtube.com/@wardocspodcast Listen to the “What We Are For” Episode 47. https://bit.ly/3r87Afm   WarDocs- The Military Medicine Podcast is a Non-Profit, Tax-exempt-501(c)(3) Veteran Run Organization run by volunteers. All donations are tax-deductible and go to honoring and preserving the history, experiences, successes, and lessons learned in Military Medicine. A tax receipt will be sent to you. WARDOCS documents the experiences, contributions, and innovations of all military medicine Services, ranks, and Corps who are affectionately called "Docs" as a sign of respect, trust, and confidence on and off the battlefield,demonstrating dedication to the medical care of fellow comrades in arms.     Follow Us on Social Media Twitter: @wardocspodcast Facebook: WarDocs Podcast Instagram: @wardocspodcast LinkedIn: WarDocs-The Military Medicine Podcast YouTube Channel: https://www.youtube.com/@wardocspodcast

ROH, MLW and GCW resultsBecome a supporter of this podcast: https://www.spreaker.com/podcast/nsc-wrestling-and-gaming-podcast--4855340/support.

Tiffany Stevenson (Former CPO, WeightWatchers), Jennifer Rettig (CPO, Pendo.io), and Kelli Dragovich (4x CHRO & Co-host of HR Heretics), joined us for MPL Live in San Francisco.We talked about the pressure HR leaders are under, what CEOs are really thinking, and how we can reimagine performance with simpler systems, clearer expectations, and more human conversations.---- Sponsor Links:

On this week's episode: Dice Coach Dials In Dice Sets Demons House Edge We also touch on sniping, 2-V mutant, ADT, negative progressions, black jack, stop loss and Ed teaches us some Greek. Call The Casino Tears Vent Line 229-NO SEVEN (667-3836) Now! Leave a message, ask a question or simply get something off your mind -  We might even play it on air!! NEW EPISODES DROP WEEKLY ON TUESDAYS - Please visit our home page at casinotears.com for more info, merch, and host contacts Extended versions will also drop Tuesdays on Patreon - Don't miss out :) Email: noseven@casinotears.com Patreon: https://www.patreon.com/CasinoTears Pro Shop: https://www.casinotears.vegas/shop/  Instagram: https://www.instagram.com/casinotearspodcast YouTube: https://www.youtube.com/@CasinoTears X: https://x.com/CasinoTears Reddit: https://www.reddit.com/r/casinotears  

Jessica Zwaan joined us again on The Modern People Leader to break down how to hire for a people ops as a product team.She shared the 5 core skillsets needed, the importance of t-shaped talent, and how to use case studies to spot product thinking in HR Candidates.---- Sponsor Links:

Nick James discusses intriguing data from STAMPEDE to us AI to analyze pathology slides to predict benefit from ADT + abiraterone

Alison and Amanda talk about the routine of renting clothes, curious encounters with customer support, savvy shopping strategies, and the days of dialing for time.  Sis & Tell, an award-winning weekly comedic podcast, is hosted by southern Jewish sisters the Emmy-nominated Alison Goldstein Lebovitz from PBS' The A List and Time Magazine's 2006 Person of the Year, Comedian Amanda Goldstein Marks.

Matt McFarlane and Haris Ikram joined us for a live session to break down everything modern HR leaders need to know about compensation—from philosophy and strategy to pay transparency and AI tools. Together, they shared a forward-thinking playbook for tackling merit cycles, aligning job architecture, and driving better employee experiences through data and design.---- Sponsor Links:

My guest this week is DeLu Jackson, Executive Vice President and Chief Marketing and Communications Officer at ADT. A seasoned executive with over 20 years of experience, DeLu has led marketing transformation at some of the world's most iconic brands, including McDonald's, Audi, Kellogg's, Nissan, Subaru, ConAgra, and now ADT. He's known for his data-driven, customer-first approach and for helping redefine what protection and connection mean in the smart home and small business security space. With an undergraduate degree in Politics from Princeton University and an MBA from NYU Stern School of Business, he brings both intellectual rigor and real-world results to the table. He's also an independent board director and a recognized thought leader in marketing, growth, and digital innovation. 

My guest today is Nigel Jones who is making his third appearance on the Tribe Sober podcast – our conversations always get plenty of downloads and Nigel is a mine of valuable information! In this episode:- Nigel's secret to success was becoming a non-drinker from Day One — rather than a drinker trying to quit. He used the metaphor of a mountain — put yourself on top from the start rather than struggling to climb it. It's our beliefs and values shape our identity, then it's our identity that drives our intentions and actions. We need to flip our beliefs: once we truly believe that alcohol is a poison, then everything changes. Nigel is a qualified Hypnotherapist and he came up with a great analogy to explain how hypnotherapy works Our conscious mind is often resistant and has “bouncers” to prevent new information from entering our subconscious Hypnotherapy can remove those bouncers allowing better access to the subconscious Drinking creates a program in our subconscious and hypnotherapy helps us to replace it with healthier programs. Nigel is also qualified in NLP - Neuro Linguistic Programming which can help us to rewire our beliefs We both agreed that Drinking is deeply tribal — Nigel calls the Alcohol Drinking Tribe the ADT People protect their ADT which is why we often encounter resistance when we announce that we have quit drinking When we leave the ADT, we need to find another tribe quickly so that we don't feel isolated or judged In fact Connection is the opposite of addiction and That's why we set up Tribe Sober which offers connection, vulnerability, and authenticity  – so if you're ready to swop your drinking tribe for Tribe Sober then click here to check out our membership program Nigel shares his own inspiring story called Walking Back to Happiness He's also a certified hypnotherapist, NLP practitioner and life coach. He offers 1:1 and group coaching, for habit change, phobias, and anxiety. His website and social media is 9kmby9am.com  Nigel's previous podcast interviews with Tribe Sober are here and here   Episode Sponsor This episode is sponsored by the Tribe Sober Membership Program.  If you want to change your relationship with alcohol then sign up today - here is the link.  Help us to spread the word! We made this podcast so that we can reach more people who need our help.  Please subscribe and share. We release a podcast episode every Saturday morning. You can follow Tribe Sober on Facebook, Twitter and Instagram.  You can join our private Facebook group HERE PS: How to Leave a Rating/Review in Apple Podcasts (on an iOS Device) Open the Podcasts app. EASY. Choose “Search” from the bottom row of icons and enter the name of the show (e.g. Recover Like a Mother) into the search field. Select the show under Shows (not under Episodes). Scroll down past the first few episodes until you see Ratings & Reviews. Click Write a Review underneath the displayed reviews from other listeners. You'll then have the option to rate the show on a 5-star scale and write a review (you can rate without writing too but it's always good to read your experience).  

Abby Brennan joined us on The Modern People Leader. We discussed the power of ONA as the “shadow org chart,” how it reveals hidden influencers, and why it may be key to building smarter, more connected teams in the age of AI.---- Sponsor Links:

AUA2025: Embracing Multi-Disciplinary Care for Advanced Prostate Cancer: A Case-Based Update 2025 CME Available: https://auau.auanet.org/node/42997 At the conclusion of this activity, participants will be able to: 1. Initial Management of Metastatic Prostate Cancer: Evaluate and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be skilled to offer novel oral antiandrogens. Furthermore, to recognize high-volume new M1 prostate cancer so as to be able to partner with GU medical oncologist for docetaxel chemotherapy in a multidisciplinary team. 2. Non-Metastatic Castrate Resistant Prostate Cancer (M0 CRPC): The learner will be skilled to diagnose M0 CRPC and be able to educate patients about using either enzalutamide or apalutamide or darolutamide added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these three oral agents and to educate patients about side-effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease Non-metastatic Castrate-Resistant Prostate Cancer (M0 CRPC): Diagnose M0 CRPC and be able to educate patients about using novel oral antiandrogens added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these novel oral agents and to educate patients about side effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease state. 3. Metastatic Castrate-Resistant Prostate Cancer (M1 CRPC): Describe and have a working knowledge of the latest phase III RCT results for new therapies in M1 CRPC and be able to educate their patients on treatment options and participate in a multidisciplinary team caring for men with this disease state of far-advanced prostate cancer. 4. Describe that advanced prostate cancer is a complex group of disease states with an ever-changing therapeutic landscape and for providers and teams to embrace the multi-disciplinary nature of care for our patients. 5. Identify the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, immune checkpoint agents, and novel AR targeted agents emerging in 2025 and beyond.

On this episode of the podcast, cancer researcher, physician, and author Dr. Steven Quay dives into President Joe Biden's recent cancer disclosure and sheds light on his broader medical history — including brain aneurysms, pulmonary embolisms, and past cancers. Dr. Quay breaks down the slow progression of prostate cancer, raising questions about the timing and transparency of Biden's newly revealed diagnosis. He also highlights the importance of PSA screenings after age 50 and explores the risks and benefits of androgen deprivation therapy (ADT).Furthermore, Dr. Quay discusses his forthcoming book, “The Code as Witness: The COVID Genome Reveals Its Lab Origins and How to Prevent Future Outbreaks,” where he makes the case for COVID's lab-based origins and calls for a federal ban on gain-of-function research to prevent future pandemics.Follow Dr. Steven Quay on X by searching for his handle: @Quay_Dr and learn more at www.DrQuay.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jessica Zwaan joined us again on The Modern People Leader to unpack how to structure a people ops as a product team. She shared four ways to build an HR squad, how to use a spider diagram for squad design, and why it's smart to pilot just one squad first.---- Sponsor Links:

这是一个独属于女性的夜晚。4月27日，耐克全球女子夜跑系列赛After Dark Tour来到上海，3500名女性跑者在南京东路集结，将上海的夜「跑为己有」。10公里结束，她们在跑百巷再次聚首，聊聊这段旅程中的汗水、成长与感动。本期节目，运动博主孙佳祺、赵依侬客串我们的代班主播，和跑龄两个月的「老跑者」颜如晶、在训练过程里能同时拥有天使和魔鬼两幅面孔的小彩教练，以及20位参赛跑者一起「续摊儿」，不仅回味了一番After DarkTour强烈的后劲，还有轻松的跑步趣事和坚韧的女性内核：当我们穿上跑鞋，不只是踏上赛道，更是在一步步中靠近那个更坚定、更自由的自己。- 聊天的人 -代班主播：孙佳祺、赵依侬嘉宾：颜如晶，耐克女子夜跑参赛者小彩，耐克NRC 城市教练ADT参赛者和跑者- 时间轴 -01:47 After Dark Tour之后，跑百巷迎来一场「全女局」05:19 颜如晶：为了准备这场10K，我先去跑了个半马10:14 从「厌跑」到半马，是怎么一步步跑起来的18:43 参加ADT的跑者们，发枪前后的反差也太大了28:26 全女赛事的特别之处？垃圾很少，还香香的32:45 在舞台一样的赛道上跑步，是种什么体验？36:32 这是属于我的勋章，不需要任何人帮忙戴上37:43 在这个夜晚，女性之间的温暖连结悄然发生39:27 夜跑的「危险」主要体现在...夜宵的诱惑？49:00 夜幕降临，正是探索城市新样貌的好时机53:36 虽然都说不忘初心，但过程有时更有意义01:01:15 不用比较，跑步是一项完全由你自己掌控的运动01:04:37 出来跑步，最重要的是先「出来」01:06:43 泡泡跑、动物园跑、胶片跑，怎么有趣怎么跑！01:09:42 跑步没那么难，但科学训练才是跑得久的秘诀01:12:17 当我们穿上跑鞋、走上赛道，成为真正的自己- 本节目由耐克出品，JustPod制作发行 -- 制作团队 -策划：孙佳祺、赵依侬、Jimmy、Tiara、王童语统筹：Cora、王冰倩制作：王童语声音设计：陆佳杰、马若晨节目运营：邓逸轩

Bryan Power, Head of People at Nextdoor, joined us on The Modern People Leader. We talked about how the company is navigating its “third era” under the return of co-founder Nirav Tolia. We explored “The Founders Mentality”, embracing an owner's mindset, and Nextdoor's AI bootcamp.---- Sponsor Links:

Today on the Dr. Geo Prostate Podcast, we're joined by world-renowned oncologist Dr. Rana McKay of UC San Diego Health. With training from Harvard and Dana-Farber, Dr. McKay breaks down the evolving landscape of triplet therapy—a combination of ADT, an ARPI (androgen receptor pathway inhibitor), and chemotherapy (docetaxel)—and how it's changing survival outcomes for men with advanced prostate cancer.In this enlightening and practical episode, Dr. Geo and Dr. McKay discuss:What triplet therapy is and how it compares to doublet therapyThe latest clinical trials and the importance of timing treatmentHow to personalize care for high- and low-volume metastatic prostate cancerWhen to escalate treatment—and when quality of life may outweigh aggressive therapyThe role of genomic tools like the Decipher score in decision-makingSide effect profiles, cold therapy, fasting, and integrative strategiesWhy communication and patient values should drive treatment decisionsIf you or a loved one is facing a diagnosis of advanced prostate cancer, this episode offers invaluable clarity and hope.

Jessica Zwaan, COO at Talentful and author of Built for People,  joined us on The Modern People Leader.We talked about “human ops” versus “people ops”, the sprint planning process for her people team, and how nobody gets people ops as a product 100% right (and that's ok).---- Sponsor Links:

Reggie Marable is the Head of Global Sales at Sierra, a conversational AI platform for businesses. Sierra enables companies like ADT, Sonos, SiriusXM, and WeightWatchers to build AI agents that transform customer experiences. The company has rapidly become a hypergrowth leader in Silicon Valley, recently securing a funding round that values it at $4.5 billion. Before joining Sierra, Reggie was the Head of Sales in North America at Slack and the Area Vice President of Enterprise Sales at Salesforce.  In Today's Episode We Discuss:  02:50 “What I Learned from Failing Early as a CRO” 06:06 The Most Effective Sales Strategy and the BS Sales Methodology 06:55 How to Build Sales Processes from Scratch 12:28 When and How to do Verticalised Sales Teams 14:15 How to Become World Class as Sales Prospecting and Outbound 17:21 How to Use Proof of Concepts to Win Enterprise Deals 22:04 Enterprise vs. Self-Serve: Both or One and How 30:09 Building a Sales Team from Scratch 37:39 Structuring the Hiring Process 41:14 How Founders F*** Up Hiring in Sales 46:25 Handling Salary and Title Expectations 51:36 How to Run Effective Deal Cycles 57:06:07 How to do Onboarding for New Sales Hires 59:07:48 How to do Post Mortems in Sales Processes 01:04:24 Negotiating Enterprise Deals 01:08:04 Quick Fire Round: Sales Tactics and Strategies